Teva Pharmaceutical Industries Ltd.

Biopharmaceuticals at Teva

Biopharmaceuticals at Teva

Teva is investing in biopharmaceuticals as part of our long term strategy for the future, and to help patients around the world. We are focusing on treatments for the central nervous system, respiratory conditions, and in the field of oncology.

Biosimilars

Biopharmaceuticals are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalized treatment.Together with creating original biologic medicines, Teva is investing in biosimilars. These are highly similar versions of reference biological treatments.A focus on biosimilars is a natural progression for Teva following our role in the development of the generic medicine industry over the past 40 years. They combine our strength in generics with our knowledge of complex medicine.Biosimilars offer value-based treatment that is potentially less expensive than the originator biologic but similarly effective. For example, it is estimated that the use of biosimilars will save the US $54 billion over 10 years.